ACB $0.833 (3%)

ACNNF $0.133 (46.15%)

AERO $1.300 (4.84%)

AGEEF $0.080 (-0.12%)

ALEAF $0.265 (0.87%)

AMMJ $0.093 (-11.22%)

APHA $2.890 (1.05%)

ARNA $43.990 (7.95%)

ATT:CNX $0.080 (0%)

ATTBF $0.007 (0%)

AUSA:CNX $0.185 (2.78%)

AUSAF $0.122 (-7.65%)

AVXL $2.630 (-6.74%)

BAMM:CNX $0.260 (1.96%)

BBM:CNX $0.065 (-7.14%)

BBRRF $0.044 (-0.23%)

BE:CNX $0.015 (0%)

BIO:CNX $0.045 (0%)

BLEVF $0.015 (0%)

BLO:CNX $0.385 (-3.75%)

BLOZF $0.278 (-3.12%)

BUDZ $0.237 (-3.18%)

BXNG $0.260 (0%)

CADMF $0.442 (2.77%)

CALI:CNX $0.070 (-12.5%)

CANN $0.460 (0.55%)

CARA $12.700 (2.5%)

CBII:CNX $0.085 (21.43%)

CBIIF $0.058 (9.95%)

CBWTF $0.246 (-1.99%)

CGC $13.800 (1.62%)

CGRW $0.055 (-5.01%)

CHOO:CNX $0.090 (-5.26%)

CHOOF $0.067 (7.26%)

CNAB $0.057 (-6.39%)

CNBX $0.159 (-6.41%)

CNGGF $0.470 (4.44%)

CODI $13.010 (2.2%)

CPMD $0.750 (-12.79%)

CRBP $4.890 (2.09%)

CRON $5.420 (3.44%)

CRTPF $1.890 (0.47%)

CRXPF $0.026 (-13.76%)

CSI:CNX $0.600 (-1.64%)

CTST $0.638 (0%)

CURR $2.188 (5.07%)

CVSI $0.510 (-8.11%)

DIGP $0.071 (0%)

DXBRF $0.140 (0%)

EAPH $0.001 (0%)

EAT:CNX $0.020 (0%)

EEVVF $0.064 (5.23%)

EMHTF $0.101 (-11.56%)

EPWCF $0.030 (0%)

EVIO $0.029 (11.76%)

FFRMF $0.021 (2.19%)

FFT:CNX $0.030 (0%)

FNNZF $0.060 (14.29%)

GGTTF $0.072 (1.87%)

GLDFF $0.012 (-10.69%)

GLH:CNX $0.020 (0%)

GNBT $0.500 (-5.66%)

GRIN:CNX $0.100 (5.26%)

GRWG $3.360 (0%)

GSTR:CNX $0.040 (0%)

GTBIF $5.788 (6.99%)

GTII:CNX $8.250 (6.59%)

GWPH $84.520 (-0.56%)

HEXO $0.723 (5.34%)

HHPHF $0.015 (0%)

HLSPY $0.490 (16.69%)

HMLSF $3.968 (0.17%)

HMPPF $0.498 (0%)

HRVOF $0.064 (6.83%)

HSTRF $0.040 (32.89%)

HUGE:CNX $5.120 (2.4%)

IAN:CNX $0.680 (6.25%)

IGC $0.450 (0.96%)

IGXT $0.159 (11.97%)

IIPR $68.920 (-0.19%)

IMLFF $0.147 (-0.54%)

INQD $0.001 (100%)

IONC:CNX $0.010 (0%)

IONKF $0.008 (-6.25%)

ISOL:CNX $0.085 (-29.17%)

ISOLF $0.064 (-20.13%)

ITHUF $0.470 (5.41%)

IVITF $0.038 (38.89%)

JWCAF $0.019 (-53.64%)

KALTF $0.011 (7.69%)

KBEV:CNX $0.085 (-5.56%)

KBEVF $0.064 (-0.87%)

KHRNF $0.397 (-3.17%)

KSHB $0.580 (0%)

LHS:CNX $0.435 (-3.33%)

LHSIF $0.310 (-2.74%)

LOVE:CNX $0.075 (0%)

LXLLF $0.380 (0%)

LXRP $0.285 (1.79%)

LXX:CNX $0.395 (-9.2%)

MCIG $0.030 (7.83%)

MDCL $1.300 (-6.47%)

MEDIF $1.054 (3.29%)

MGWFF $0.040 (-16.14%)

MICWF $0.027 (65.22%)

MJ:CNX $0.020 (-42.86%)

MJNA $0.015 (-1.35%)

MNTR $0.100 (0.76%)

MRRCF $0.006 (13.27%)

MWM:CNX $0.035 (16.67%)

MYM:CNX $0.060 (0%)

MYMMF $0.040 (-11.11%)

NCNNF $0.108 (12.19%)

NDVAF $0.156 (-2.56%)

NGW:CNX $0.065 (0%)

NRXCF $0.018 (-13.06%)

NSPDF $0.023 (40.24%)

NTEC $0.182 (-5.75%)

NVTQF $0.099 (0%)

NWKRF $0.424 (0%)

NXGWF $0.047 (-3.13%)

NXTTF $0.210 (3.35%)

ORHOF $4.050 (0%)

OWCP $0.010 (0%)

PHVAF $0.047 (0%)

PILL:CNX $0.390 (-4.88%)

PKG:CNX $0.090 (0%)

PLPRF $0.433 (-4.25%)

PLUS:CNX $0.610 (5.17%)

PMCB $0.029 (-2.03%)

PNPL $0.210 (0%)

POTN $0.012 (0%)

PRCNF $0.016 (44.14%)

PTNYF $0.066 (-1.92%)

QCA:CNX $0.060 (0%)

RDDTF $0.126 (-3.56%)

RLLVF $0.026 (267%)

RMHB $0.018 (-9.55%)

RQB:CNX $0.010 (0%)

RQHTF $0.280 (0%)

RVVQF $0.007 (-42.86%)

SLNG:CNX $0.185 (-2.63%)

SMG $103.420 (2.65%)

SNN:CNX $0.180 (-5.26%)

SNNVF $0.129 (7.3%)

SOL:CNX $0.240 (-2.04%)

SOLCF $0.171 (0.53%)

SPLIF $0.019 (26.67%)

SPRWF $0.209 (12.97%)

SRNA $0.024 (-19.32%)

STEM:CNX $0.540 (5.88%)

STMH $0.365 (4.29%)

SUN:CNX $0.090 (-5.26%)

TBPMF $0.162 (1.38%)

TCAN:CNX $0.750 (1.35%)

TCNAF $0.510 (-7.46%)

TER:CNX $2.430 (-0.82%)

TGEN $0.910 (-4.21%)

TGIF:CNX $0.090 (12.5%)

TGIFF $0.062 (7.89%)

THC:CNX $0.100 (0%)

THCBF $0.063 (1.61%)

TLRY $6.100 (3.39%)

TOKI:CNX $0.015 (0%)

TRLFF $0.020 (-20.4%)

TRPX $0.325 (-5.52%)

TRSSF $1.692 (-1.65%)

TRTC $0.072 (-7.62%)

TURV $0.040 (8.11%)

VBIO $0.030 (0%)

VIDA:CNX $0.060 (9.09%)

VIN:CNX $0.020 (0%)

VPRB $0.015 (0.67%)

VRNDF $0.317 (14.86%)

VRT:CNX $0.150 (0%)

VRTHF $0.102 (0%)

VVCIF $0.149 (-1.47%)

WAYL:CNX $0.740 (0%)

WDDMF $0.295 (4.8%)

WLDFF $0.065 (-7.14%)

XXII $0.680 (-0.01%)

ZDPY $0.139 (1.61%)

ZYNE $3.470 (1.76%)

Back

Empower Clinics Announces Strong Start to The Year with January 2020 Patient Visits Increasing by 188%

Feb 11, 2020 • 7:01 AM EST
4 MIN READ  •  By Anthony Varrell
Share Share - Facebook Share - Twitter

EMPOWER CLINICS INC. (CSE:CBDT)(OTC:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company is pleased to announce that patient visits in corporate clinics increased by 188% in January 2020 versus the same period in 2019, with total patient visits of 1,750 in January 2020 compared to 607 in January 2019.

“January patient volumes were strong, setting the stage for potentially record first quarter patient visits, that are always focused on the patient experience, it’s a competitive advantage and I continue to be impressed with how our team members care for each and every patient they see.” said Steven McAuley, Chairman & CEO of Empower. “Looking forward, we are excited for our next franchise signings and the expansion of our product lines, adding to the in-clinic retail experience we are building.”

The Company utilizes it’s technology platform to communicate with patients by text message, email and call center ensuring appointments are confirmed and expected patient visits take place as planned.

The Company’s Sun Valley Health division also completed the set up and build out of it’s retail product counter and sales areas in it’s Tucson, AZ location, to showcase it’s CBD product line with over 50 unique SKU’s. Patients and customers can purchase product in clinic locations or online at www.sunvalleyhealth.com.

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

CEO

s.mcauley@empowerclinics.com

604-789-2146

Investors: Dustin Klein
SVP, Business Development
dustin@svmmjcc.com
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: rs@maricom.ca, T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

View source version on accesswire.com:
https://www.accesswire.com/576033/Empower-Clinics-Announces-Strong-Start-to-The-Year-with-January-2020-Patient-Visits-Increasing-by-188

 

Source: ACCESSWIRE (February 11, 2020 – 3:30 AM EST)

News by QuoteMedia
www.quotemedia.com

Share Share - Facebook Share - Twitter

Tags

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Technical420 newsletter.

 All good -- no spamming here.